Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Fluad (MF59C.1-adjuvanted trivalent influenza vaccine) in Adults ≥65 Years
2013-000607-16Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fluzone Trivalent in influenza, sponsored by Novartis. Primary endpoints: Immunogenicity endpoints and Safety endpoints. Started Mar 2013; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on 2013-000607-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000607-16.